CD19 CAR T cells have shown a stable antitumor efficacy in patients with recurrent B cell acute lymphoblastic leukemia (B-ALL), CLL, and non-Hodgkin’s lymphoma (NHL) in recent years [13]. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.